Daniela Gompelmann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Daniela Gompelmann has a total of 560 co-authors. Here are the top co-authors by number of shared publications:
Ralf Eberhardt
Thoraxklinik at Heidelberg University Hospital, Heidelberg, Germany
36 shared publications- Felix J. F. Herth
Pneumology and Critical Care Medicine, Thoraxklinik, University of Heidelberg, Heidelberg, Germany
31 shared publications Fjf Herth
Pneumologie und Beatmungsmedizin, Thoraxklinik, Universität Heidelberg, Translationales Lungenforschungszentrum (Tlrch), Deutsches Zentrum für Lungenforschung (Dzl)
23 shared publicationsR Eberhardt
Pneumologie und Beatmungsmedizin, Thoraxklinik, Universität Heidelberg, Translationales Lungenforschungszentrum (Tlrch), Deutsches Zentrum für Lungenforschung (Dzl)
22 shared publicationsR. Eberhardt
14 shared publicationsMaren Schuhmann
Pneumology and Critical Care Medicine, Thoraxklinik, University of Heidelberg, Heidelberg, Germany
12 shared publications
Latest Publications
- 27 October 2026
- Published by Springer Nature in Zeitschrift für Pneumologie
- Vol. 23 (6) , 327-328
Von Prä-COPD bis zum Endstadium
- 27 October 2026
- Published by Springer Nature in Zeitschrift für Pneumologie
- Vol. 23 (6) , 327-328
Von Prä-COPD bis zum Endstadium
- Open Access
Impact of Residual Mediastinal Nodal Disease After Neoadjuvant Chemoimmunotherapy for Non-Small Cell Lung Cancer
Background/Objectives: In recent years, neoadjuvant chemoimmunotherapy followed by surgery has improved outcomes in patients with stage II/III non-small cell lung cancer (NSCLC). However, the prognostic impact of residual mediastinal nodal disease after chemoimmunotherapy remains insufficiently defined, particularly with the introduction of the Union for International Cancer Control/American Joint Committee on Cancer (UICC/AJCC) 9th edition nodal subclassification. Methods: In this retrospective study, 90 consecutive patients with clinically node-positive (cN1-2) resectable locally advanced NSCLC who underwent neoadjuvant chemoimmunotherapy followed by curative-intent resection were included. Disease-free survival (DFS) was analyzed according to postoperative pathologic nodal status. Nodal status was assessed using the UICC/AJCC 8th edition (ypN0, ypN1, ypN2) and reclassified according to the 9th edition (ypN0, ypN1, ypN2a, ypN2b). Residual postoperative nodal disease was defined as residual pathologic nodal involvement (ypN+) in patients with clinically node-positive (cN+) disease at baseline. Results: The cohort comprised 90 patients (60% male, median age 63 years [interquartile range (IQR) 58–69]). Following neoadjuvant therapy, surgery revealed pathologic nodal clearance in 53 (58.9%) and residual nodal disease in 37 (41.1%) patients (ypN1, n = 16 [17.8%]; ypN2a, n = 15 [16.7%]; and ypN2b, n = 6 [6.7%]). DFS differed significantly by postoperative nodal status (global log-rank p < 0.001), with progressively poorer outcomes with increasing residual nodal burden. Conclusions: Residual nodal disease after neoadjuvant chemoimmunotherapy and surgery is associated with progressively inferior DFS according to its anatomic extent. The UICC/AJCC 9th-edition staging system provides clinically relevant prognostic granularity, supporting further investigation of mediastinal restaging and postoperative treatment strategies.
Open AccessImpact of Residual Mediastinal Nodal Disease After Neoadjuvant Chemoimmunotherapy for Non-Small Cell Lung Cancer
Background/Objectives: In recent years, neoadjuvant chemoimmunotherapy followed by surgery has improved outcomes in patients with stage II/III non-small cell lung cancer (NSCLC). However, the prognostic impact of residual mediastinal nodal disease after chemoimmunotherapy remains insufficiently defined, particularly with the introduction of the Union for International Cancer Control/American Joint Committee on Cancer (UICC/AJCC) 9th edition nodal subclassification. Methods: In this retrospective study, 90 consecutive patients with clinically node-positive (cN1-2) resectable locally advanced NSCLC who underwent neoadjuvant chemoimmunotherapy followed by curative-intent resection were included. Disease-free survival (DFS) was analyzed according to postoperative pathologic nodal status. Nodal status was assessed using the UICC/AJCC 8th edition (ypN0, ypN1, ypN2) and reclassified according to the 9th edition (ypN0, ypN1, ypN2a, ypN2b). Residual postoperative nodal disease was defined as residual pathologic nodal involvement (ypN+) in patients with clinically node-positive (cN+) disease at baseline. Results: The cohort comprised 90 patients (60% male, median age 63 years [interquartile range (IQR) 58–69]). Following neoadjuvant therapy, surgery revealed pathologic nodal clearance in 53 (58.9%) and residual nodal disease in 37 (41.1%) patients (ypN1, n = 16 [17.8%]; ypN2a, n = 15 [16.7%]; and ypN2b, n = 6 [6.7%]). DFS differed significantly by postoperative nodal status (global log-rank p < 0.001), with progressively poorer outcomes with increasing residual nodal burden. Conclusions: Residual nodal disease after neoadjuvant chemoimmunotherapy and surgery is associated with progressively inferior DFS according to its anatomic extent. The UICC/AJCC 9th-edition staging system provides clinically relevant prognostic granularity, supporting further investigation of mediastinal restaging and postoperative treatment strategies.
- Open Access
- 22 June 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (12) , 4834
Prognostic Value of Bronchoalveolar Lavage in Systemic Autoimmune Rheumatic Diseases-Associated Interstitial Lung Disease
Background: Systemic autoimmune rheumatic diseases-associated interstitial lung disease (SARD-ILD) presents with varied disease courses, emphasizing the need for reliable predictors of progression. The prognostic utility of bronchoalveolar lavage (BAL) in SARD-ILD remains underexplored. The objective of this study was to evaluate the role of BAL fluid lymphocyte count in predicting disease progression in patients with SARD-ILD. Methods: This observational study included patients with SARD-ILD undergoing BAL as part of their diagnostic workup. Disease progression was defined as either Forced vital capacity (FVC) decrease >10%, two out of the following three criteria within two years: FVC decrease of 5–10%, worsening symptoms, increased fibrosis on imaging, or any of the following: escalation of treatment, Interstitial lung disease (ILD) exacerbation, lung transplantation, or disease-specific mortality. Logistic regression identified predictors of progression. Time-to-progression was assessed using Kaplan–Meier survival curves. The optimal BAL lymphocyte threshold for predicting progression was identified using the Youden Index and the Wilcoxon method. Results: We identified 89 patients, of whom 30 (33.7%) had progressive disease. Progressors had a significantly higher BAL lymphocyte count compared to non-progressors (31.6 ± 24.8% vs. 14.3 ± 16.5%, p < 0.001). BAL lymphocyte proportion was significantly and independently associated with disease progression (odds ratio, 1.05; 95% confidence interval 1.02–1.07; p < 0.01). A lymphocyte count above 9 percent was associated with a markedly increased risk of disease progression (odds ratio, 13.14; 95% confidence interval, 4.20–51.98; p < 0.01). Conclusions: BAL lymphocyte count was associated with a higher likelihood of progression in SARD-ILD. BAL assessment may help identify patients at increased risk of disease progression. However, these findings should be considered exploratory and require validation in larger prospective studies and across individual SARD-ILD subtypes.
- 22 June 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (12) , 4834
Open AccessPrognostic Value of Bronchoalveolar Lavage in Systemic Autoimmune Rheumatic Diseases-Associated Interstitial Lung Disease
Background: Systemic autoimmune rheumatic diseases-associated interstitial lung disease (SARD-ILD) presents with varied disease courses, emphasizing the need for reliable predictors of progression. The prognostic utility of bronchoalveolar lavage (BAL) in SARD-ILD remains underexplored. The objective of this study was to evaluate the role of BAL fluid lymphocyte count in predicting disease progression in patients with SARD-ILD. Methods: This observational study included patients with SARD-ILD undergoing BAL as part of their diagnostic workup. Disease progression was defined as either Forced vital capacity (FVC) decrease >10%, two out of the following three criteria within two years: FVC decrease of 5–10%, worsening symptoms, increased fibrosis on imaging, or any of the following: escalation of treatment, Interstitial lung disease (ILD) exacerbation, lung transplantation, or disease-specific mortality. Logistic regression identified predictors of progression. Time-to-progression was assessed using Kaplan–Meier survival curves. The optimal BAL lymphocyte threshold for predicting progression was identified using the Youden Index and the Wilcoxon method. Results: We identified 89 patients, of whom 30 (33.7%) had progressive disease. Progressors had a significantly higher BAL lymphocyte count compared to non-progressors (31.6 ± 24.8% vs. 14.3 ± 16.5%, p < 0.001). BAL lymphocyte proportion was significantly and independently associated with disease progression (odds ratio, 1.05; 95% confidence interval 1.02–1.07; p < 0.01). A lymphocyte count above 9 percent was associated with a markedly increased risk of disease progression (odds ratio, 13.14; 95% confidence interval, 4.20–51.98; p < 0.01). Conclusions: BAL lymphocyte count was associated with a higher likelihood of progression in SARD-ILD. BAL assessment may help identify patients at increased risk of disease progression. However, these findings should be considered exploratory and require validation in larger prospective studies and across individual SARD-ILD subtypes.
- Open Access
- 15 June 2026
- Published by Springer Nature in Zeitschrift für Pneumologie
- Vol. 23 (6) , 361-366
Endoskopische Therapie der COPD
Zusammenfassung: Die endoskopische Lungenvolumenreduktion stellt eine minimalinvasive Therapieoption bei Patient*innen mit fortgeschrittenem Emphysem dar, die trotz einer maximalen konservativen Therapie symptomatisch sind. Die endoskopische Ventiltherapie, deren Effektivität bei Emphysempatient*innen mit fehlender interlobärer Kollateralventilation in zahlreichen randomisiert kontrollierten Studien belegt werden konnte, ist mittlerweile im klinischen Alltag etabliert. Bei Patient*innen mit relevanter Kollateralventilation stehen ebenfalls endoskopische Therapien zur Verfügung, die jedoch aufgrund geringer Datenlage im Rahmen von Studien nach individueller Benefit-Risiko-Abwägung erfolgen sollten. Essenziell für den Erfolg jeder dieser Therapiemethoden sind die präzise Patientenselektion und die interdisziplinäre Indikationsstellung in einem Emphysemboard.
- 15 June 2026
- Published by Springer Nature in Zeitschrift für Pneumologie
- Vol. 23 (6) , 361-366
Open AccessEndoskopische Therapie der COPD
Zusammenfassung: Die endoskopische Lungenvolumenreduktion stellt eine minimalinvasive Therapieoption bei Patient*innen mit fortgeschrittenem Emphysem dar, die trotz einer maximalen konservativen Therapie symptomatisch sind. Die endoskopische Ventiltherapie, deren Effektivität bei Emphysempatient*innen mit fehlender interlobärer Kollateralventilation in zahlreichen randomisiert kontrollierten Studien belegt werden konnte, ist mittlerweile im klinischen Alltag etabliert. Bei Patient*innen mit relevanter Kollateralventilation stehen ebenfalls endoskopische Therapien zur Verfügung, die jedoch aufgrund geringer Datenlage im Rahmen von Studien nach individueller Benefit-Risiko-Abwägung erfolgen sollten. Essenziell für den Erfolg jeder dieser Therapiemethoden sind die präzise Patientenselektion und die interdisziplinäre Indikationsstellung in einem Emphysemboard.
- Open Access
- 28 April 2026
- Published by MDPI AG in Journal of Respiration
- Vol. 6 (2) , 7
Bacterial Load in Bronchial Washing Fluid Samples of Patients Undergoing Proton Pump Inhibitor Therapy: A Retrospective Observational Study Using Fluorescein as a Marker of Micro-Aspiration
Background: Proton pump inhibitors (PPIs) have been associated with lung dysbiosis and increased respiratory risk. Micro-aspiration is a proposed mechanism, but reliable biomarkers remain elusive. This study evaluates the potential of fluorescein as a biomarker of micro-aspiration and PPI-associated pulmonary risk. Methods: We conducted a retrospective analysis of 137 bronchial washing fluid samples from patients with pulmonary conditions to assess microbial colonization in relation to PPI use. Bacterial burden was determined by culture and PCR and categorized as 0, 1 or ≥2 pathogens. Micro-aspiration was evaluated by quantifying fluorescein-laden macrophages in bronchoalveolar lavage following oral fluorescein administration. Associations between PPI use, fluorescein levels and pathogen burden were analyzed using adjusted ordinal regression models. Results: PPI use was associated with higher odds of increased pathogen burden, though not statistically significant (OR = 1.40, 95% CI: 0.71–2.75, p = 0.33). Fluorescein-laden macrophages were higher in PPI users (41.5 versus 31.2 ng/mL), but showed no meaningful correlation with pathogen load (p = 0.09). Corticosteroid therapy was significantly associated with Gram stain results (OR = 2.37, 95% CI: 1.12–5.15, p = 0.03). Conclusions: These findings suggest a potential link between PPI use and airway colonization. Fluorescein shows promise as a biomarker for micro-aspiration, but its clinical utility requires further validation.
- 28 April 2026
- Published by MDPI AG in Journal of Respiration
- Vol. 6 (2) , 7
Open AccessBacterial Load in Bronchial Washing Fluid Samples of Patients Undergoing Proton Pump Inhibitor Therapy: A Retrospective Observational Study Using Fluorescein as a Marker of Micro-Aspiration
Background: Proton pump inhibitors (PPIs) have been associated with lung dysbiosis and increased respiratory risk. Micro-aspiration is a proposed mechanism, but reliable biomarkers remain elusive. This study evaluates the potential of fluorescein as a biomarker of micro-aspiration and PPI-associated pulmonary risk. Methods: We conducted a retrospective analysis of 137 bronchial washing fluid samples from patients with pulmonary conditions to assess microbial colonization in relation to PPI use. Bacterial burden was determined by culture and PCR and categorized as 0, 1 or ≥2 pathogens. Micro-aspiration was evaluated by quantifying fluorescein-laden macrophages in bronchoalveolar lavage following oral fluorescein administration. Associations between PPI use, fluorescein levels and pathogen burden were analyzed using adjusted ordinal regression models. Results: PPI use was associated with higher odds of increased pathogen burden, though not statistically significant (OR = 1.40, 95% CI: 0.71–2.75, p = 0.33). Fluorescein-laden macrophages were higher in PPI users (41.5 versus 31.2 ng/mL), but showed no meaningful correlation with pathogen load (p = 0.09). Corticosteroid therapy was significantly associated with Gram stain results (OR = 2.37, 95% CI: 1.12–5.15, p = 0.03). Conclusions: These findings suggest a potential link between PPI use and airway colonization. Fluorescein shows promise as a biomarker for micro-aspiration, but its clinical utility requires further validation.
- Open Access
- 24 February 2026
- Published by Georg Thieme Verlag KG in Pneumologie
- Vol. 80 (04) , 290-296
Kongresse der deutschen und österreichischen Gesellschaft für Pneumologie 2025: Highlights aus dem Bereich der Interventionellen Pneumologie
Zusammenfassung: Dieser Artikel fasst die Highlights im Bereich der interventionellen Pneumologie der Kongresse der deutschen Gesellschaft für Pneumologie (DGP) im April 2025 und der österreichischen Gesellschaft für Pneumologie (ÖGP) im Oktober 2025 zusammen. In inspirierenden und abwechslungsreichen Kongressprogrammen wurden zahlreiche prospektive und retrospektive Studien vorgestellt, die wertvolle Erkenntnisse im Bereich der interventionellen Pneumologie geliefert und neue Perspektiven eröffnet haben. Wesentliche Themen umfassten Innovationen im Bereich der endoskopischen Rundherddiagnostik und -therapie sowie neue Entwicklungen im Gebiet der endoskopischen Lungenvolumenreduktion.
- 24 February 2026
- Published by Georg Thieme Verlag KG in Pneumologie
- Vol. 80 (04) , 290-296
Open AccessKongresse der deutschen und österreichischen Gesellschaft für Pneumologie 2025: Highlights aus dem Bereich der Interventionellen Pneumologie
Zusammenfassung: Dieser Artikel fasst die Highlights im Bereich der interventionellen Pneumologie der Kongresse der deutschen Gesellschaft für Pneumologie (DGP) im April 2025 und der österreichischen Gesellschaft für Pneumologie (ÖGP) im Oktober 2025 zusammen. In inspirierenden und abwechslungsreichen Kongressprogrammen wurden zahlreiche prospektive und retrospektive Studien vorgestellt, die wertvolle Erkenntnisse im Bereich der interventionellen Pneumologie geliefert und neue Perspektiven eröffnet haben. Wesentliche Themen umfassten Innovationen im Bereich der endoskopischen Rundherddiagnostik und -therapie sowie neue Entwicklungen im Gebiet der endoskopischen Lungenvolumenreduktion.
- 2 January 2026
- Published by Springer Nature
- p. 467-474
Y-Stenting Techniques
- 1 January 2026
- Published by Tech Science Press in Oncology Research
- p. 1-10
Prognostic Value of Nodal Downstaging after Neoadjuvant Chemoimmunotherapy for Non-Small Cell Lung Cancer
Background: The significance of nodal downstaging after neoadjuvant chemoimmunotherapy in patients with resectable stage II–III non-small cell lung cancer (NSCLC) remains incompletely characterized. This study evaluates the prognostic value of nodal downstaging after neoadjuvant chemoimmunotherapy followed by curative resection according to the 9th edition of the UICC/AJCC nodal classification. Methods: This retrospective study included 90 patients with node-positive stage II–III NSCLC who underwent neoadjuvant chemoimmunotherapy followed by surgery between 2017 and 2025 at the Department of Thoracic Surgery, Medical University of Vienna, Austria. Baseline and postoperative nodal stages were classified according to the 9th edition of the UICC/AJCC staging system. Disease-free survival (DFS) was analyzed according to nodal response patterns, and the association between nodal downstaging and major pathologic response (MPR) was evaluated. Results: Patients who achieved nodal downstaging had significantly longer DFS compared with those without nodal downstaging (3-year DFS rates: 73.6% vs. 42.2%; p = 0.009). DFS differed significantly by the depth of nodal response (p = 0.009), with the most favorable outcomes observed in patients achieving complete nodal clearance compared with partial or no downstaging (3-year DFS: 77.3%, 57.1%, and 42.2%, respectively). PD-L1 expression ≥50% was associated with an increased likelihood of nodal downstaging compared with PD-L1 <50% (OR 3.25, 95% CI 1.19–8.61, p = 0.022), and nodal downstaging was significantly associated with MPR (OR 4.31, 95% CI 1.42–13.09; p = 0.010). Conclusion: Nodal downstaging after neoadjuvant chemoimmunotherapy was associated with improved DFS in resectable node-positive NSCLC. The extent of nodal response provides clinically relevant prognostic stratification.
- 1 January 2026
- Published by Tech Science Press in Oncology Research
- p. 1-10
Prognostic Value of Nodal Downstaging after Neoadjuvant Chemoimmunotherapy for Non-Small Cell Lung Cancer
Background: The significance of nodal downstaging after neoadjuvant chemoimmunotherapy in patients with resectable stage II–III non-small cell lung cancer (NSCLC) remains incompletely characterized. This study evaluates the prognostic value of nodal downstaging after neoadjuvant chemoimmunotherapy followed by curative resection according to the 9th edition of the UICC/AJCC nodal classification. Methods: This retrospective study included 90 patients with node-positive stage II–III NSCLC who underwent neoadjuvant chemoimmunotherapy followed by surgery between 2017 and 2025 at the Department of Thoracic Surgery, Medical University of Vienna, Austria. Baseline and postoperative nodal stages were classified according to the 9th edition of the UICC/AJCC staging system. Disease-free survival (DFS) was analyzed according to nodal response patterns, and the association between nodal downstaging and major pathologic response (MPR) was evaluated. Results: Patients who achieved nodal downstaging had significantly longer DFS compared with those without nodal downstaging (3-year DFS rates: 73.6% vs. 42.2%; p = 0.009). DFS differed significantly by the depth of nodal response (p = 0.009), with the most favorable outcomes observed in patients achieving complete nodal clearance compared with partial or no downstaging (3-year DFS: 77.3%, 57.1%, and 42.2%, respectively). PD-L1 expression ≥50% was associated with an increased likelihood of nodal downstaging compared with PD-L1 <50% (OR 3.25, 95% CI 1.19–8.61, p = 0.022), and nodal downstaging was significantly associated with MPR (OR 4.31, 95% CI 1.42–13.09; p = 0.010). Conclusion: Nodal downstaging after neoadjuvant chemoimmunotherapy was associated with improved DFS in resectable node-positive NSCLC. The extent of nodal response provides clinically relevant prognostic stratification.
- Open Access
- 1 July 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (13) , 1677
Management and Outcomes of Pulmonary Nodules in a Real-World Setting
Background and Objective: Due to the increasing use of imaging and lung cancer screening programs, the rate of detected pulmonary nodules has steadily increased over the past decade. Overall, the diagnosis and management of pulmonary nodules remain challenging. Moreover, no specific guidelines exist for the management of pulmonary nodules in patients with a history of previous malignancy. This study reflects the current management in a real-world setting in a specialized European center. Methods: In this retrospective single-center study, patients with a pulmonary nodule p < 0.001), showed a progression in size (p < 0.001), and were found to be malignant more frequently when compared to patients without previous cancer (p = 0.032). Conclusions: As most patients referred to a specialized center represent a selected group of high-risk patients, the majority of pulmonary nodules were found to be malignant. In patients with a history of previous malignancy, tissue sampling is warranted as the rate of malignancy is high.
- 1 July 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (13) , 1677
Open AccessManagement and Outcomes of Pulmonary Nodules in a Real-World Setting
Background and Objective: Due to the increasing use of imaging and lung cancer screening programs, the rate of detected pulmonary nodules has steadily increased over the past decade. Overall, the diagnosis and management of pulmonary nodules remain challenging. Moreover, no specific guidelines exist for the management of pulmonary nodules in patients with a history of previous malignancy. This study reflects the current management in a real-world setting in a specialized European center. Methods: In this retrospective single-center study, patients with a pulmonary nodule p < 0.001), showed a progression in size (p < 0.001), and were found to be malignant more frequently when compared to patients without previous cancer (p = 0.032). Conclusions: As most patients referred to a specialized center represent a selected group of high-risk patients, the majority of pulmonary nodules were found to be malignant. In patients with a history of previous malignancy, tissue sampling is warranted as the rate of malignancy is high.
- Open Access
The Mesothelioma Systemic Inflammation Score Is Independently Associated with Overall Survival and Predicts Benefit of Multimodality Treatment in Pleural Mesothelioma
Background/Objectives: Malignant pleural mesothelioma (MPM) remains challenging to treat, with a poor prognosis. As controversy about clinical management continues, predictive biomarkers for patient selection to indicate the benefit of treatment modalities are urgently needed. Methods: In a retrospective analysis of 195 patients between 1994 and 2020 at the Department of Thoracic Surgery, Medical University of Vienna, Austria, the Mesothelioma Systemic Inflammation Score (MSIS)—consisting of pretreatment neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), C-reactive protein (CRP), and fibrinogen—was tested for its prognostic and predictive significance. The prognostic impact of MSIS was subsequently validated in an independent cohort of 80 patients treated at the Department of Thoracic Surgery, Karl Landsteiner Institute for Clinical and Translational Thoracic Surgery Research, Clinic Floridsdorf, Vienna, Austria. Results: Median overall survival (OS) was 14 months for the entire cohort (95% CI: 11.4–16.6). Patients undergoing multimodality treatment including macroscopic complete resection had a longer OS (22.3 months, 95% CI: 18.6–26.0; p < 0.001). In multivariable analysis, MSIS (p < 0.001), disease stage (p = 0.001), and the type of treatment (p = 0.004) were confirmed as independent predictors for OS. Higher MSIS was associated with shorter OS (p < 0.001). Significant survival benefit of multimodality regimens including surgery was limited to patients with low MSIS. Among patients with low (≤ 2) MSIS, multimodality therapy was associated with significantly prolonged OS when compared with chemo- and/or radiotherapy alone (25.8 months [95% CI: 16.4–35.3] vs. 14.4 months [95% CI: 10.4–18.4], p < 0.001). In contrast, among patients with elevated MSIS, no survival benefit was achieved by surgery over conservative treatment (11.8 months [95% CI: 8.3–15.3] vs. 8.2 months [95% CI: 5.2–11.3], p = 0.233). The ability of MSIS to predict survival was equivalent between the baseline and the independent validation cohort (p < 0.001). Conclusions: The Mesothelioma Systemic Inflammation Score was found to be an independent prognostic score in pleural mesothelioma, predicting benefit from macroscopic complete resection as part of multimodality treatment in distinct patients.
Open AccessThe Mesothelioma Systemic Inflammation Score Is Independently Associated with Overall Survival and Predicts Benefit of Multimodality Treatment in Pleural Mesothelioma
Background/Objectives: Malignant pleural mesothelioma (MPM) remains challenging to treat, with a poor prognosis. As controversy about clinical management continues, predictive biomarkers for patient selection to indicate the benefit of treatment modalities are urgently needed. Methods: In a retrospective analysis of 195 patients between 1994 and 2020 at the Department of Thoracic Surgery, Medical University of Vienna, Austria, the Mesothelioma Systemic Inflammation Score (MSIS)—consisting of pretreatment neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), C-reactive protein (CRP), and fibrinogen—was tested for its prognostic and predictive significance. The prognostic impact of MSIS was subsequently validated in an independent cohort of 80 patients treated at the Department of Thoracic Surgery, Karl Landsteiner Institute for Clinical and Translational Thoracic Surgery Research, Clinic Floridsdorf, Vienna, Austria. Results: Median overall survival (OS) was 14 months for the entire cohort (95% CI: 11.4–16.6). Patients undergoing multimodality treatment including macroscopic complete resection had a longer OS (22.3 months, 95% CI: 18.6–26.0; p < 0.001). In multivariable analysis, MSIS (p < 0.001), disease stage (p = 0.001), and the type of treatment (p = 0.004) were confirmed as independent predictors for OS. Higher MSIS was associated with shorter OS (p < 0.001). Significant survival benefit of multimodality regimens including surgery was limited to patients with low MSIS. Among patients with low (≤ 2) MSIS, multimodality therapy was associated with significantly prolonged OS when compared with chemo- and/or radiotherapy alone (25.8 months [95% CI: 16.4–35.3] vs. 14.4 months [95% CI: 10.4–18.4], p < 0.001). In contrast, among patients with elevated MSIS, no survival benefit was achieved by surgery over conservative treatment (11.8 months [95% CI: 8.3–15.3] vs. 8.2 months [95% CI: 5.2–11.3], p = 0.233). The ability of MSIS to predict survival was equivalent between the baseline and the independent validation cohort (p < 0.001). Conclusions: The Mesothelioma Systemic Inflammation Score was found to be an independent prognostic score in pleural mesothelioma, predicting benefit from macroscopic complete resection as part of multimodality treatment in distinct patients.